A Targeted Literature Search and Phenomenological Review of Perspectives of People with Multiple Sclerosis and Healthcare Professionals of the Immunology of Disease-Modifying Therapies
ConclusionsThis targeted literature search and phenomenological review confirms PwMS preferences for empowered decision-making in disease management and treatment selection, to optimize independence, safety, and efficacy. It also identifies an unmet need for improved communication and information tools that convey MS information in a relatable manner. Furthermore, this review seeks to address this unmet need by providing plain language figures and descriptions of MS immune mechanisms that can be used to facilitate discussions between HCPs and PwMS. (Source: Neurology and Therapy)
Source: Neurology and Therapy - July 30, 2022 Category: Neurology Source Type: research
The Cure SMA Clinical Trial Experience Survey: A Study of Trial Participant Perspectives on Clinical Trial Management and Patient-Centric Management Practices
ConclusionThis research provides new perspective on patient experiences in SMA clinical trials. It underscores the importance of information and efforts to anticipate and accommodate participant needs. These findings may inform study design and interactions with research participants. They may become especially important in supporting recruitment and retention as more treatment options become available. (Source: Neurology and Therapy)
Source: Neurology and Therapy - July 30, 2022 Category: Neurology Source Type: research
Patterns of Utilization and Expenditure Across Multiple Sclerosis Disease-Modifying Therapies: A Retrospective Cohort Study Using Claims Data from a Commercially Insured Population in the United States, 2010 –2019
ConclusionDMT cost is a key driver of the overall healthcare expenditure in MS. Future comparative and cost-effectiveness studies integrating claims and electronic health records data with better balancing of patient characteristics are warranted. (Source: Neurology and Therapy)
Source: Neurology and Therapy - July 30, 2022 Category: Neurology Source Type: research
Functional Specificity of TPS Brain Stimulation Effects in Patients with Alzheimer ’s Disease: A Follow-up fMRI Analysis
ConclusionResults argue for a high functional specificity of ultrasound-based neuromodulation with TPS. (Source: Neurology and Therapy)
Source: Neurology and Therapy - July 30, 2022 Category: Neurology Source Type: research
Autologous Hematopoietic Stem-Cell Transplantation in Multiple Sclerosis: A Systematic Review and Meta-Analysis
ConclusionCurrent data encourages a broader application of AHSCT for treating patients with MS while still considering proper patient selection and transplant methods. In addition, with increasing knowledge and expertise in the field of stem-cell therapy, AHSCT has become a safer treatment approach for MS. (Source: Neurology and Therapy)
Source: Neurology and Therapy - July 28, 2022 Category: Neurology Source Type: research
Physician-Reported Perspectives on Myasthenia Gravis in the United States: A Real-World Survey
ConclusionsOur findings indicated that, despite treatment, there is a proportion of patients with MG in the US who had a significant need for improved disease management. (Source: Neurology and Therapy)
Source: Neurology and Therapy - July 20, 2022 Category: Neurology Source Type: research
A Response to: Letter to the Editor regarding “COVID-19-Related Burden and Risk Perception in Individuals with Chronic Inflammatory Demyelinating Polyneuropathy and Multifocal Motor Neuropathy: A Cross-Sectional Study”
(Source: Neurology and Therapy)
Source: Neurology and Therapy - July 16, 2022 Category: Neurology Source Type: research
Letter to the Editor regarding “COVID-19-Related Burden and Risk Perception in Individuals with Chronic Inflammatory Demyelinating Polyneuropathy and Multifocal Motor Neuropathy: A Cross-Sectional Study”
(Source: Neurology and Therapy)
Source: Neurology and Therapy - July 16, 2022 Category: Neurology Source Type: research
Real-World Assessment of Quality of Life in Patients with Relapsing Remitting Multiple Sclerosis Treated with Teriflunomide for Two Years: Patient-Reported Outcomes from the AURELIO Study in Greece
ConclusionsThese data highlight the importance of PROs to facilitate personalized treatment strategies in MS. In line with other teriflunomide studies, AURELIO showed stable QoL, efficacy and safety outcomes, and good treatment satisfaction both in treatment-na ïve and previously treated patients in this Greek cohort of patients with RRMS. (Source: Neurology and Therapy)
Source: Neurology and Therapy - July 13, 2022 Category: Neurology Source Type: research
Interrater and Intrarater Agreement of Epileptic Encephalopathy Among Electroencephalographers for Children with Infantile Spasms Using the Burden of Amplitudes and Epileptiform Discharges (BASED) EEG Grading Scale: Study Design and Statistical Considerations
DiscussionWe will recruit more electroencephalographers than were included in previous studies to assess the interrater and intrarater agreement in the selection of 5-min EEG epochs, the BASED scores, and the basis for scoring. If the BASED score has an adequate interrater and intrarater agreement, the score will have more significance for guiding the clinical management and for predicting the prognosis of patients with infantile spasms. (Source: Neurology and Therapy)
Source: Neurology and Therapy - July 9, 2022 Category: Neurology Source Type: research
Standard Dose Weekly Intramuscular Beta Interferon-1a May Be Inadequate for Some Patients with Multiple Sclerosis: A 19-Year Clinical Experience Using Twice a Week Dosage
ConclusionFor patients with MS having breakthrough disease on QW INF β1a, switching to more frequently administered INFβ may be an option. Advantages to using IM INFβ1a for this include no skin reactions and a lower incidence of neutralizing antibodies. Further pragmatic, observational, larger-group studies comparing treatment with Avonex® and higher dosed IM INF β1a, such as the recently FDA-approved IM peginterferon beta-1a, may be indicated. (Source: Neurology and Therapy)
Source: Neurology and Therapy - July 7, 2022 Category: Neurology Source Type: research
Safety, Tolerability, Pharmacokinetics and Initial Pharmacodynamics of a Subcommissural Organ-Spondin-Derived Peptide: A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose First-in-Human Study
ConclusionNX210 is safe and well tolerated and may exert beneficial effects on the central nervous system, particularly in terms of cognitive processing. (Source: Neurology and Therapy)
Source: Neurology and Therapy - July 2, 2022 Category: Neurology Source Type: research
Letter to the Editor Regarding “Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder”
(Source: Neurology and Therapy)
Source: Neurology and Therapy - July 2, 2022 Category: Neurology Source Type: research
A Response to: Letter to the Editor Regarding “Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder”
(Source: Neurology and Therapy)
Source: Neurology and Therapy - July 2, 2022 Category: Neurology Source Type: research
Patient Experience in Early-Stage Parkinson ’s Disease: Using a Mixed Methods Analysis to Identify Which Concepts Are Cardinal for Clinical Trial Outcome Assessment
ConclusionPatient experiences in early-stage PD are complex and wide-ranging, and the currently available patient-reported outcome (PRO) instruments do not evaluate many early-stage PD concepts such asfunctional slowness, fine motor skills, and subtle gait abnormalities. The development of a new PRO instrument, created in conjunction with people with PD, that fully assesses symptoms and the experience of living with early-stage PD, is required. (Source: Neurology and Therapy)
Source: Neurology and Therapy - July 1, 2022 Category: Neurology Source Type: research
